SAGE Therapeutics Inc.'s postpartum depression drug brexanolone may see its patient population limited by US FDA requirements for continuous monitoring and lack of home use.
If approved, brexanolone, which is purported to be a positive allosteric modulator of GABAA receptors, would be the first therapy...





